LDTs Rule Update: More Support for Legal Challenges Against FDA
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
The latest regulatory, legal, compliance, and technology news for labs and pathology practices.
Key clinical laboratory organizations file amicus brief, reiterating that the FDA is overstepping its authority, and its new rule would cause “irreparable patient harm”
While likely not a surprise to medical labs, a new report may add more urgency to solving recruitment and retention issues.
We’re inviting our readers to share their ideas for topics and presenters, both for future standalone webinars and our virtual events.
The Final Rule caps future PAMA cuts at 15 percent per calendar year.
A California health system will pony up $13 million to settle reference lab billing fraud claims.
In response to the latest data on repeat testing, on Nov. 1, the agency made a few changes to EUAs for such tests.
A doctor settles alleged FCA violations involving genetic tests, while a clinical lab owner pleads guilty for his role in another scheme.
Mobile phlebotomist services have become a dynamic new segment of the medical labs market.
Learn about the current state of the No Surprises Act, challenges in compliance, and how to navigate the law.
Medicare Administrative Contractors are shortchanging labs on monkeypox test reimbursement, association says.
The healthcare services provider will be on the hook for $13 million for alleged improper billing of lab tests.